The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study
Open accessAbstract
OBJECTIVE: To describe liver disease related mortality in the United States during 1999-2016 by age group, sex, race, cause of liver disease, and geographic region. DESIGN: Observational cohort study. SETTING: Death certificate data from the Vital Statistics Cooperative, and population data from the US Census Bureau compiled by the Center for Disease Control and Prevention's Wide-ranging Online Data for Epidemiologic Research (1999-2016). PARTICIPANTS: US residents. MAIN OUTCOME MEASURE: Deaths from cirrhosis and hepatocellular carcinoma, with trends evaluated using joinpoint regression. RESULTS: From 1999 to 2016 in the US annual deaths from cirrhosis increased by 65%, to 34 174, while annual deaths from hepatocellular carcinoma doubled to 11 073. Only one subgroup-Asians and Pacific Islanders-experienced an improvement in mortality from hepatocellular carcinoma: the death rate decreased by 2.7% (95% confidence interval 2.2% to 3.3%, P<0.001) per year. Annual increases in cirrhosis related mortality were most pronounced for Native Americans (designated as "American Indians" in the census database) (4.0%, 2.2% to 5.7%, P=0.002). The age adjusted death rate due to hepatocellular carcinoma increased annually by 2.1% (1.9% to 2.3%, P<0.001); deaths due to cirrhosis began increasing in 2009 through 2016 by 3.4% (3.1% to 3.8%, P<0.001). During 2009-16 people aged 25-34 years experienced the highest average annual increase in cirrhosis related mortality (10.5%, 8.9% to 12.2%, P<0.001), driven entirely by alcohol related liver disease. During this period, mortality due to peritonitis and sepsis in the setting of cirrhosis increased substantially, with respective annual increases of 6.1% (3.9% to 8.2%) and 7.1% (6.1% to 8.4%). Only one state, Maryland, showed improvements in mortality (-1.2%, -1.7% to -0.7% per year), while many, concentrated in the south and west, observed disproportionate annual increases: Kentucky 6.8% (5.1% to 8.5%), New Mexico 6.0% (4.1% to 7.9%), Arkansas 5.7% (3.9% to 7.6%), Indiana 5.0% (3.8% to 6.1%), and Alabama 5.0% (3.2% to 6.8%). No state showed improvements in hepatocellular carcinoma related mortality, while Arizona (5.1%, 3.7% to 6.5%) and Kansas (4.3%, 2.8% to 5.8%) experienced the most severe annual increases. CONCLUSIONS: Mortality due to cirrhosis has been increasing in the US since 2009. Driven by deaths due to alcoholic cirrhosis, people aged 25-34 have experienced the greatest relative increase in mortality. White Americans, Native Americans, and Hispanic Americans experienced the greatest increase in deaths from cirrhosis. Mortality due to cirrhosis is improving in Maryland but worst in Kentucky, New Mexico, and Arkansas. The rapid increase in death rates among young people due to alcohol highlight new challenges for optimal care of patients with preventable liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Permutation tests for joinpoint regression with applications to cancer rates
Kim, H.-J., Fay, M. P., Feuer, E. J., & Midthune, D. N. (2000) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(20000215)19:3<335::aid-sim336>3.0.co;2-z · Cited by 6,318
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
Angeli, P., Bernardi, M., Villanueva, C., Francoz, C., Mookerjee, R. P., Trebicka, J., Krag, A., Laleman, W., & Gines, P. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.024 · Cited by 2,905
(2013) · Gastroenterology Research · doi:10.1053/j · Cited by 2,759
D'Amico, G., Garcia-Tsao, G., & Pagliaro, L. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.013 · Cited by 2,687
Estes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,399
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
Altekruse, S. F., McGlynn, K. A., & Reichman, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7753 · Cited by 1,694
Estimating average annual per cent change in trend analysis
Clegg, L. X., Hankey, B. F., Tiwari, R., Feuer, E. J., & Edwards, B. K. (2009) · Statistics in Medicine · doi:10.1002/sim.3733 · Cited by 1,256
Cited by
Cao, W., Chen, H.-D., Yu, Y.-W., Li, N., & Chen, W.-Q. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001474 · Cited by 2,865
Global burden of liver disease: 2023 update
Devarbhavi, H., Asrani, S. K., Arab, J. P., Nartey, Y. A., Pose, E., & Kamath, P. S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.017 · Cited by 2,267
Sepanlou, S. G., Safiri, S., Bisignano, C., Ikuta, K. S., Merat, S., Saberifiroozi, M., Poustchi, H., Tsoi, D., Colombara, D. V., Abdoli, A., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30349-8 · Cited by 1,714
Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis
Moon, A. M., Singal, A. G., & Tapper, E. B. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.07.060 · Cited by 1,150
Self-citationCrabb, D. W., Im, G. Y., Szabo, G., Mellinger, J. L., & Lucey, M. R. (2020) · Hepatology · doi:10.1002/hep.30866 · Cited by 922
Global epidemiology of cirrhosis — aetiology, trends and predictions
Huang, D. Q., Terrault, N. A., Tacke, F., Gluud, L. L., Arrese, M., Bugianesi, E., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00759-2 · Cited by 839
Peery, A. F., Crockett, S. D., Murphy, C. C., Jensen, E. T., Kim, H. P., Egberg, M. D., Lund, J. L., Moon, A. M., Pate, V., Barnes, E. L., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2021.10.017 · Cited by 836
Paik, J. M., Golabi, P., Younossi, Y., Mishra, A., & Younossi, Z. M. (2020) · Hepatology · doi:10.1002/hep.31173 · Cited by 788
Changing epidemiology, global trends and implications for outcomes of NAFLD
Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.036 · Cited by 765
Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors
Huang, D. Q., Mathurin, P., Cortez-Pinto, H., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00688-6 · Cited by 553
Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction
Kanwal, F., & Singal, A. G. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.049 · Cited by 471
Single-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosis
Dobie, R., Wilson-Kanamori, J. R., Henderson, B. E. P., Smith, J. R., Matchett, K. P., Portman, J. R., Wallenborg, K., Picelli, S., Zagorska, A., Pendem, S. V., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.024 · Cited by 420
“Mortality rates secondary to liver cirrhosis continue to increase, with no Food and Drug Administration (FDA)- or European Medicines Agency (EMA)-approved antifibrotic treatments currently available, and liver transplantation only accessible to a select few (Friedman et al., 2018; Koyama et al., 2016; Tapper and Parik…”
BackgroundDiagnosis and Management of Cirrhosis and Its Complications: A Review
Tapper, E. B., & Parikh, N. D. (2023) · JAMA · doi:10.1001/jama.2023.5997 · Cited by 392
Self-citationAlcohol consumption and risk of liver cirrhosis: a systematic review and meta-analysis
Roerecke, M., Vafaei, A., Hasan, O. S. M., Chrystoja, B. R., Cruz, M., Lee, R., Neuman, M. G., & Rehm, J. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000340 · Cited by 391
Alcohol-associated liver disease
Mackowiak, B., Fu, Y., Maccioni, L., & Gao, B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci176345 · Cited by 359
Kumar, S., Duan, Q., Wu, R., Harris, E. N., & Su, Q. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113869 · Cited by 351
White, A. M., Castle, I. P., Hingson, R. W., & Powell, P. A. (2020) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.14239 · Cited by 318
Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population
Graupera, I., Thiele, M., Serra-Burriel, M., Caballeria, L., Roulot, D., Wong, G. L.-H., Fabrellas, N., Guha, I. N., Arslanow, A., Expósito, C., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.034 · Cited by 295
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Vogel, A., Chan, S. L., Dawson, L. A., Kelley, R. K., Llovet, J. M., Meyer, T., Ricke, J., Rimassa, L., Sapisochin, G., Vilgrain, V., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.02.006 · Cited by 281
Liver fibrosis: Pathophysiology and clinical implications
Berumen, J., Baglieri, J., Kisseleva, T., & Mekeel, K. (2021) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1499 · Cited by 259
Wong, R. J., & Singal, A. K. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.20294 · Cited by 253
Yang, J. D., Ahmed, F., Mara, K. C., Addissie, B. D., Allen, A. M., Gores, G. J., & Roberts, L. R. (2020) · Hepatology · doi:10.1002/hep.30858 · Cited by 209
“(1, 2) (3) While chronic hepatitis C virus infection (HCV) has been the leading cause of HCC in the US for the past several decades, successful treatment of chronic hepatitis C (HCV) with highly potent direct antiviral treatment is decreasing the disease burden of HCV, and thus decreasing the number of HCV associated…”
BackgroundThe intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00822-y · Cited by 207
“the occurrence of ALD might be increasing, especially among young people 51 .”
BackgroundMacrophages in the Aging Liver and Age-Related Liver Disease
Stahl, E. C., Haschak, M. J., Popovic, B., & Brown, B. N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02795 · Cited by 171
Cost-effectiveness of hepatocellular carcinoma surveillance: an assessment of benefits and harms
Parikh, N. D., Singal, A. G., Hutton, D. W., & Tapper, E. B. (2020) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000715 · Cited by 163
Self-citationAlcohol-associated liver disease—Global epidemiology
Åberg, F., Jiang, Z. G., Cortez-Pinto, H., & Männistö, V. (2024) · Hepatology · doi:10.1097/hep.0000000000000899 · Cited by 163
Drug-induced stress responses and addiction risk and relapse
Wemm, S. E., & Sinha, R. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100148 · Cited by 144
The role of FGF21 and its analogs on liver associated diseases
Falamarzi, K., Malekpour, M., Tafti, M. F., Azarpira, N., Behboodi, M., & Zarei, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.967375 · Cited by 94
Simon, T. G., Kim, M. N., Luo, X., Yang, W., Ma, Y., Chong, D. Q., Fuchs, C. S., Meyerhardt, J. A., Corey, K. E., Chung, R. T., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.12.022 · Cited by 57
Management of alcohol use disorder in patients with chronic liver disease
Mellinger, J. L., Fernandez, A. C., & Winder, G. S. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000145 · Cited by 52
“[2] Over a 16-year period, mortality for all-cause cirrhosis rose 65%, but these increases were almost entirely due to rises in ALD mortality, especially among young people ages 25–34 and women.[3] Globally, increases in both compensated and decompensated alcohol–associated cirrhosis have also been demonstrated, risin…”
BackgroundLucey, M. R. (2019) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.09.013 · Cited by 39
Vannier, A. G. L., Przybyszewski, E. M., Shay, J., Patel, S. J., Schaefer, E., Goodman, R. P., & Luther, J. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.08.001 · Cited by 38
Dickerson, D. L., D'Amico, E. J., Klein, D. J., Johnson, C. L., Hale, B., Ye, F., & Dominguez, B. X. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108439 · Cited by 24
Verma, M., Horrow, J., & Navarro, V. (2019) · Hepatology Communications · doi:10.1002/hep4.1328 · Cited by 23
“647 associated with complex psychosocial comorbidities, including alcohol use disorder (increasingly among the young population)(7,8) and substance abuse, both of which occur more frequently and at a greater severity among patients with CLD than the general population.”
BackgroundTop-Down Proteomics Identifies Plasma Proteoform Signatures of Liver Cirrhosis Progression
Forte, E., Sanders, J. M., Pla, I., Kanchustambham, V. L., Hollas, M. A. R., Huang, C.-F., Sanchez, A., Peterson, K. N., Melani, R. D., Huang, A., et al. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100876 · Cited by 22
Muthiah, M. D., Huang, D. Q., Zhou, L., Jumat, N. H., Choolani, M., Chan, J. K. Y., Wee, A., Lim, S. G., & Dan, Y.-Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-51189-7 · Cited by 15
Zhang, R., Tang, Z., Xu, W., Ding, Y., Zhang, M., Guan, Q., Jiang, R., Chen, Y., Hua, Y., & Wang, J. (2022) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.14951 · Cited by 14
The boomer penalty: excess mortality among baby boomers in Canada and the United States
Acosta, E., Gagnon, A., Ouellette, N., Bourbeau, R. R., Nepomuceno, M., & van Raalte, A. A. (2020) · doi:10.4054/mpidr-wp-2020-003 · Cited by 5
Metadata
- Authors
- Tapper, E. B., & Parikh, N. D.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2018-07-18
- Volume
- 362
- Pages
- k2817
- ISSN
- 1756-1833 (ISSN-L)
- 0959-8138
- OpenAlex
- W2883047299
- Cited by
- 856
- References
- 42
- FWCI
- 60.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.